You are here: Industry Insights > VTE

News List

Psoriasis Ups Risk for Vascular Disease, Venous Thromboembolism Drugs
December 08, 2021
There is an increased risk for venous thromboembolism (VTE) and peripheral vascular disease (PVD) among patients with psoriatic disease, according to a review published online Dec. 1 in JAMA Dermatology.
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban Drugs
December 07, 2021
For patients with venous thromboembolism (VTE), new users of apixaban have lower rates of recurrent VTE and bleeding compared with new users of rivaroxaban, according to a study published online Dec. 7 in the Annals of Internal Medicine.
Bayer’s Xarelto approved in the UK pharmatimes
February 02, 2021
Bayer’s oral factor Xa inhibitor Xarelto (rivaroxaban) has been approved in the UK to treat venous thromboembolism (VTE) and to prevent VTE recurrence in children.
Metabolic Syndrome May Up Risk for VTE Recurrence After DVT drugs
January 20, 2020
For patients with deep vein thrombosis (DVT), the presence of any component of metabolic syndrome (MetS) is independently associated with an increased risk for venous thromboembolism (VTE) recurrence ...
Risk for Blood Clots Increased With PICC Placement in Children drugs
January 20, 2020
Central venous catheter (CVC) placement with peripherally inserted central catheters (PICCs) in children is associated with increased risks for venous thromboembolism (VTE), central line-associated bloodstream infection (CLABSI) ...
World Thrombosis Day Empowers People Around the World to Recognize and Help Prevent Life-Threatening Blood Clots En-CPhI.CN
October 11, 2019
On October 13, the World Thrombosis Day campaign shares an important message: patients, regardless of where they live ...
SAVED Score Can Predict Risk for VTE in Multiple Myeloma drugs
August 19, 2019
For patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), a risk assessment model, SAVED, can predict the risk for venous thromboembolism (VTE)...
New Score Predicts Risk for VTE in Those With Multiple Myeloma drugs
August 08, 2019
A new risk prediction score outperforms current guidelines for predicting venous thromboembolism (VTE) in multiple myeloma (MM), according to a study published online in the American Journal of Hematology
BI announces Dabigatran's safety and efficacy for management of VTE in children biospectrumasia
July 10, 2019
Pradaxa is not approved in any country for paediatric patients with VTE.
FDA Approves First Anticoagulant for Pediatric Patients to Treat VTE americanpharmaceuticalreview
May 23, 2019
The U.S. Food and Drug Administration (FDA) has approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.

Previous page 1 2 Next page